WHO Raises Concern Over Severe Scarcity of Weight-Loss Injections
Less than 10% of people who could benefit from weight-loss injections including Wegovy are able to get them, caution the World Health Organization as it releases its inaugural recommendations on the therapies.
With in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for more widespread and fairer availability to this class of drugs.
According to forecasts, over two billion are projected to be living with obesity by 2030 without intervention.
"The new guidelines recognises that obesity is a chronic disease that can be addressed with comprehensive and ongoing care," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are major obstacles to broad access to the jabs that can aid individuals in losing considerable weight, explains the agency.
Weight-Loss Drug Supply Crisis
Despite the current most favorable scenario, the supply of such drugs might only reach around 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The guideline calls on governments and firms to expand availability, by approaches including patent sharing.
Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is set to lapse in a number of nations in 2026.
How Weight-Loss Injections Work
GLP-1 drugs mimick a body's own hormone to delay gastric emptying, suppress the appetite and boost satiety so people eat less.
Patients commonly see weight reduction after several weeks of starting on the regular doses.
Studies points to patients may regain a significant portion within a year of discontinuing the treatment, when their usual hunger return.
To be carrying excess weight elevates your chance for experiencing health problems, like diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight affects people in all nations and was linked to millions of deaths worldwide in 2024, as per the health agency.
